A Single-Dose, Open-Label, Randomized, 2-Period, 2-Sequence, Crossover Study to Determine the Effect of Food Coadministration on the Pharmacokinetics of 300 mg Canagliflozin in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 24 Oct 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 24 Oct 2011 Actual initiation date changed from May 2011 to April 2011 as reported by ClinicalTrials.gov.
- 24 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.